IDO is a nodal pathogenic driver of lung cancer and metastasis development

IDO (indoleamine 2,3-dioxygenase) enzyme inhibitors have entered clinical trials for cancer treatment based on preclinical studies indicating that they can defeat immune escape and broadly enhance other therapeutic modalities. However, clear genetic evidence of IDO’s impact on tumorigenesis in physi...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Smith, Courtney, Chang, Mee-Young, Parker, Katherine, Beury, Daniel, DuHadaway, James B., Flick, Hollie E., Boulden, Janette, Sutanto-Ward, Erika, Soler, Alejandro Peralta, Laury-Kleintop, Lisa D., Mandik-Nayak, Laura, Metz, Richard, Ostrand-Rosenberg, Suzanne, Prendergast, George C., Muller, Alexander J.
Formato: Artigo
Idioma:Inglês
Publicado: 2012
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3677576/
https://ncbi.nlm.nih.gov/pubmed/22822050
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-12-0014
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares